China Property Woes Deepen With Vanke Slump, Country Garden Halt
One of China’s biggest property firms delayed its earnings report while another posted a record profit decline as the nation’s real estate crisis shows no signs of easing.
Latest Videos
The information you requested is not available at this time, please check back again soon.
One of China’s biggest property firms delayed its earnings report while another posted a record profit decline as the nation’s real estate crisis shows no signs of easing.
The owners of Saks Fifth Avenue are in talks to raise financing to bolster the cash portion of an offer to buy competitor Neiman Marcus, according to people familiar with the matter, moving two of America’s biggest high-end department stores closer to a deal after years of on-and-off courtship.
Jefferies Financial Group Inc.’s revenue jump — due to strong capital markets and rebounding investment banking — bodes well for the bigger banks due to report in weeks to come.
Blackstone Inc. sold 48 warehouses in Southern California to Rexford Industrial Realty Inc. for $1 billion.
Plunging demand for commodity offices in the US is driving growth for the highest-quality properties, a Morgan Stanley executive said.
Jan 7, 2020
Bloomberg News
,(Bloomberg) -- I-Mab Biopharma Co., a Chinese drug developer, has launched what is set to be the first U.S. initial public offering by a Chinese biotech company in more than two years.
I-Mab started taking orders on Monday for the IPO, which could raise as much as $111 million -- down from the $200 million people familiar with the matter said last year. If the deal goes through, it will be the first U.S. listing by a Chinese biotech company since Zai Lab Ltd.’s $173 million offering in 2017, according to figures compiled by Bloomberg. Since 2004, only five biotech firms from the mainland have completed IPOs in the U.S.
Many of them have decided to go for Hong Kong instead, after the city’s stock exchange amended its listing rules in April 2018 to allow firms from the industry with no revenue to list there. I-Mab had initially considered Hong Kong before switching to the U.S., people familiar with the matter have said.
Since the rule change, 17 biotech companies from the mainland have listed in Hong Kong, raising a combined $5.12 billion, data compiled by Bloomberg show. And four more have already filed for IPOs there, with others in the pipeline. In the U.S., 47 firms from the sector raised some $5.86 billion in initial offerings last year alone.
I-Mab -- along with Californian firm Velocity Financial LLC -- will be the first American IPO of the year after a dismal 2019 for listings by Chinese companies there. The 33 that completed initial share sales last year have dropped by an average 21%, compared with a more than 17% gain for all U.S. listings.
UPCOMING LISTINGS:
Jiumaojiu International Holdings
Huijing Holdings
Shenzhen Leoking Environmental Group
More ECM situations we are following:
SEE ALSO:
To contact the reporter on this story: Julia Fioretti in Hong Kong at jfioretti4@bloomberg.net
To contact the editors responsible for this story: Lianting Tu at ltu4@bloomberg.net, Cecile Vannucci
©2020 Bloomberg L.P.